Jaramillo, S., Krisam, J., Cornet, L. L., Kratzmann, M., Baumann, L., Sauer, T., . . . Schlenk, R. F. (2021). Rationale and design of the 2 by 2 factorial design GnG-trial: A randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. BMC.
Chicago Style (17th ed.) CitationJaramillo, Sonia, et al. Rationale and Design of the 2 by 2 Factorial Design GnG-trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML. BMC, 2021.
MLA (8th ed.) CitationJaramillo, Sonia, et al. Rationale and Design of the 2 by 2 Factorial Design GnG-trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML. BMC, 2021.